CDK4/6 inhibition triggers ICAM1-driven immune response and sensitizes LKB1 mutant lung cancer to immunotherapy

Liver kinase B1 (LKB1) mutation is prevalent and a driver of resistance to immune checkpoint blockade (ICB) therapy for lung adenocarcinoma. Here leveraging single cell RNA sequencing data, we demonstrate that trafficking and adhesion process of activated T cells are defected in genetically engineer...

Descripción completa

Detalles Bibliográficos
Autores principales: Bai, Xue, Guo, Ze-Qin, Zhang, Yan-Pei, Fan, Zhen-zhen, Liu, Li-Juan, Liu, Li, Long, Li-Li, Ma, Si-Cong, Wang, Jian, Fang, Yuan, Tang, Xin-Ran, Zeng, Yu-Jie, Pan, Xinghua, Wu, De-Hua, Dong, Zhong-Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9985635/
https://www.ncbi.nlm.nih.gov/pubmed/36871040
http://dx.doi.org/10.1038/s41467-023-36892-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9985635/
https://www.ncbi.nlm.nih.gov/pubmed/36871040
http://dx.doi.org/10.1038/s41467-023-36892-4

Ejemplares similares